Aspire Submits Registration Statement for US IPO

Feb.22.2023
Aspire Submits Registration Statement for US IPO
Aspire, an e-cigarette and CBD product company, submitted registration to list on NASDAQ with an expected $155.25 million in funding.

On February 20th, the electronic cigarette and CBD product company, Aspire, filed a registration statement to go public on the US stock market.


The company intends to go public on the NASDAQ stock exchange, with a proposed maximum share price of $9 and the aim of raising $155.25 million by issuing 17.25 million shares. The registration statement provides details on the company's current operations, risk factors, and equity structure.


The parent company of Aspire, a business department, is a manufacturer of vape and CBD products. The total global retail sales of vape products from 2015 to 2020 and the retail sales forecast for 2021 to 2024 are also presented in the registration document (see chart below).


Source: US Securities and Exchange Commission


According to data, during the early days of the company's establishment (2015-17), an open system was more welcomed by the market. However, since the gradual replacement of open vaping systems with closed ones, closed systems have become the mainstream in the market and surpassed open systems in 2019. That year, the global sales of closed vaping systems reached $9.688 billion, surpassing open systems' $8.392 billion.


The company predicts that closed systems will continue to dominate the market and that global vape sales will reach $66.8 billion by 2023.


Since 2019, the company has been expanding its CBD market in the United States and Canada. In 2020, the global sales of cannabis products reached $2.9 billion.


Source: U.S. Securities and Exchange Commission


In addition, the company also undertakes OEM/ODM business for electronic atomization systems.


According to Aspire's registration document, the company's main market is Europe, with the European market accounting for 61% of the company's total performance in 2020, followed by 22.6% in the United States. Their efforts to expand in the Asia-Pacific market have been significant, increasing from 0.1% in 2019 to 9.5%.


Source: U.S. Securities and Exchange Commission.


The risk factors listed in the registration statement of the company are as follows:


Existing and newly enacted laws, regulations, and policies could present barriers to the company's future business operations and have significant adverse effects. Currently, the company can only legally sell one product, Nautilus Prime, in the US, which accounted for less than 11% of the company's US revenues in the year ending June 30, 2020. As a result, the company can no longer sell products that accounted for more than 89% of their US revenues in that same period, leading to a decline in US sales in the six months ending December 31, 2020. The market for cannabis vaporization products is still immature, with most sales occurring in the US, and expansion in the US or globally is not guaranteed. Recently, joint statements from the US Securities and Exchange Commission and the Public Company Accounting Oversight Board, proposed rule changes from NASDAQ, and a bill passed by the US Senate have all called for stricter standards when evaluating the qualifications of auditors for emerging market companies, especially those auditors that are not subject to PCAOB inspections outside of the US. These developments could increase uncertainty around the company's issuances. If there is evidence to suggest or research to show that the use of electronic vaporization or cannabis products poses long-term health risks, the use of such products could significantly decrease, which would have a substantial adverse impact on the company's business, financial condition, and operating performance. The company's operations entail inherent risks and uncertainties, including developments in regulatory environments, medical discoveries, and the market's acceptance of electronic cigarette devices. The company faces potential adverse effects due to sales, product liability, and user complaints. Misuse or abuse of the company's products could lead to potential adverse health effects, leading to complaints, product liability claims, and negative publicity. The company faces competition in the electronic vaporization industry, including larger, more well-known companies with a significantly larger market share, and Aspire may not effectively compete. In addition, widespread outbreaks of diseases, natural disasters, or improper behavior by employees or distributors could harm the company's interests and reputation and have an adverse impact on its business operations.


2FIRSTS will continue to follow this topic and provide timely updates. Stay tuned for our latest coverage.


Reference:


Aspire has filed a registration statement with the U.S. Securities and Exchange Commission.



Disclaimer

This article is provided solely for professional research, industry discussion, and informational purposes. Any references to brands, companies, products, technologies, or policies are made for factual reporting and analytical purposes only, and do not constitute endorsement, recommendation, promotion, or advertising by 2Firsts.

Nicotine-containing products, including but not limited to cigarettes, e-cigarettes, heated tobacco products, and nicotine pouches, carry significant health risks. Readers are responsible for complying with all applicable laws and regulations in their respective jurisdictions, including age restrictions and access limitations.

The information contained in this article should not be regarded as investment, legal, medical, regulatory, or commercial advice. While 2Firsts strives to ensure the accuracy and reliability of its content, it does not assume liability for any direct or indirect loss arising from errors, omissions, inaccuracies, or reliance on the information contained herein.

This article is not intended for individuals below the legal age for accessing tobacco or nicotine-related information in their jurisdiction.

 

Copyright Notice

This article is either original content produced by 2Firsts or content reproduced, translated, summarized, or adapted from third-party sources with attribution where applicable. The intellectual property rights of the original content remain with 2Firsts or the respective original rights holders.

No individual or organization may copy, reproduce, distribute, republish, modify, translate, or otherwise use this content without prior authorization. Any unauthorized use may result in legal action.

For copyright-related inquiries, corrections, or removal requests, please contact: info@2firsts.com.

 

AI-Assisted Translation and Editing Notice

Portions of this article may have been translated, edited, or reviewed with the assistance of artificial intelligence tools to improve efficiency and readability. Due to the limitations of AI-assisted translation and editing, discrepancies, omissions, or inaccuracies may exist when compared with the original source.

Where applicable, readers are advised to refer to the original source for the most complete and accurate information. If you identify any errors or believe that any content infringes upon your rights, please contact us at info@2firsts.com, and we will review and address the matter promptly.

Iowa Vape Directory Exposes Retail Divide: Specialty Vape Retailer Route 69 Vapor Says Over 98% of Its Inventory Is Unlisted, While Convenience Chains Casey’s, Maverik and Tobacco Giant Altria Previously Backed the Law
Iowa Vape Directory Exposes Retail Divide: Specialty Vape Retailer Route 69 Vapor Says Over 98% of Its Inventory Is Unlisted, While Convenience Chains Casey’s, Maverik and Tobacco Giant Altria Previously Backed the Law
Iowa published its first vapor products directory on November 16, 2026, restricting retail sales to products covered by 361 listed entries. In interviews published on November 18, independent vape retailers described inventory restrictions, revenue exposure and store closure plans. Route 69 Vapor said more than 98% of its inventory was excluded from the directory, while Central Iowa Vapors said approximately 91% of its existing product assortment was unlisted. A mixed tobacco retailer reported nearly $15,000 in vape inventory that suppliers would not accept for return. Iowa legislative records show that convenience store and fuel retail chains Casey’s and Maverik, along with tobacco company Altria, supported the legislation establishing the directory in 2024. The new rules also affect licensed distributors, wholesalers and manufacturers, bringing supply-chain arrangements into the dispute over retail access.
Regulations
Nov.19
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
NAS 2026 | Former FDA Tobacco Chief Mitch Zeller Calls for Shift From “End Game” to “End State”
At the 2026 New Approaches Summit in New York, former FDA Center for Tobacco Products Director Mitch Zeller called for the tobacco harm reduction debate to shift from the traditional “end game” toward defining a desired “end state.” He also highlighted unresolved concerns around dual use, argued that biomarkers of exposure may be more meaningful than cigarettes-per-day in assessing risk reduction, and said nicotine misperceptions remain a major barrier to public health progress.
Sep.25
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
Pennsylvania Vape Directory Law Survives Court Challenge From Nova Distro and Others Amid Similar Rulings Across States
A U.S. federal court upheld Pennsylvania's vape directory law on October 14, rejecting a challenge brought by Nova Distro, 101 Distributors and companies operating Tobacco Hut retail stores. Court records show that vaping accounts for about 60% of Tobacco Hut's profits and that the chain held approximately $2 million in inventory potentially subject to seizure under the law as of June 2. Pennsylvania began enforcement on October 19. The ruling follows similar appellate decisions in other states, even as new research shows that unlisted vaping products continue to account for substantial sales in states with established directories.
Regulations
Oct.22
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
Altria Showcases Ploom, Marlboro Heated Tobacco Sticks and Non-Nicotine Energy Products at NACS Show 2026
At the 2026 NACS Show, Altria displayed Ploom devices alongside imagery of Marlboro-branded heated tobacco sticks, while also featuring RIOT Energy and Proper Wild non-nicotine products. The booth showcased on! PLUS nicotine pouches, including 12 mg variants not listed among FDA-authorized products as of October 9, and NJOY e-cigarettes. Altria also presented convenience-store traffic figures highlighting its retail presence. 2Firsts examines the company's expanded product portfolio, non-nicotine business activities and the regulatory status of products displayed at the show.
EXPO
Oct.10
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
PMI Showcases ZYN, IQOS and U.S. Investments at NACS Show 2026
At the 2026 NACS Show in Las Vegas, Philip Morris International (PMI) showcased its ZYN nicotine pouches, IQOS heated tobacco products and U.S. investments. A 2Firsts review of FDA records found that several ZYN products displayed at the booth were not on the agency's marketing authorization list, including certain nicotine strengths and flavors. A PMI booth representative also confirmed that IQOS is currently sold in three U.S. states, while the newer IQOS ILUMA system remains under FDA review.
EXPO
Oct.10
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Product | OXVA Introduces XLIM PRO 4 With Liquid-Level Anti-Burn Technology and Dedicated Pods
Vaping brand OXVA introduced the XLIM PRO 4 refillable pod system in October 2026, featuring Anti-Burn Tech (ABT) based on smart e-liquid-level detection. The system can issue refill alerts and stop power output when e-liquid levels become too low. ABT requires the XLIM PRO 4 device and a dedicated XLIM ABT cartridge. Standard XLIM pods remain compatible but do not support ABT protection. OXVA previously introduced temperature-based anti-burn technology in the XLIM Pro 2 DNA, developed with Evolv. The new device features a 1,800mAh battery, 5–30W output and a 0.98-inch HD color screen. OXVA's official store lists the device at $37.90 and dedicated ABT replacement cartridges at $12.99. Independent testing confirmed the low-liquid protection response but recorded varying cartridge lifespans.
product
Oct.30